---
title: "Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder) in chronic obstructive pulmonary disease: Guidelines questions"
description: "Guidelines questions on Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder) in chronic obstructive pulmonary disease, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: Trelegy: what does the GOLD COPD Report say about using a single inhaler? 1 question quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease/guidelines"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder) in chronic obstructive pulmonary disease: Guidelines questions

Manufacturer: GlaxoSmithKline  
Prescribing information: [Trelegy Ellipta](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF)

Questions that apply to every indication of Trelegy Ellipta are on [Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder), all indications](https://www.evicenter.com/medical-information/trelegy-ellipta).

## Guidelines

<a id="trelegy-gold-single-inhaler"></a>

### Trelegy: what does the GOLD COPD Report say about using a single inhaler?

> “According to the GOLD COPD Report:”

Source: [TRELEGY ELLIPTA: Dosing & Delivery, captured 2026-11-14](https://www.trelegyhcp.com/dosing-and-delivery/#:~:text=According%20to%20the%20GOLD%20COPD%20Report%3A)

> “Minimizing the number of different inhaler types is suggested for patients as using a single inhaler improves adherence<sup>9</sup>”

Source: [TRELEGY ELLIPTA: Dosing & Delivery, captured 2026-11-14](https://www.trelegyhcp.com/dosing-and-delivery/#:~:text=Minimizing%20the%20number%20of%20different,using%20a%20single%20inhaler%20improves)

Note: The statement concerns inhaler regimens in general and does not name TRELEGY.

## Related pages
- [Medical information: Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder): Chronic obstructive pulmonary disease](https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease)
- [Indication](https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease/clinical-trials)
- [Real-world evidence](https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease/real-world-evidence)
- [Safety](https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease/safety)
- [Drug interactions](https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease/storage-and-supply)
